Roche Looks Beyond Protease Inhibitors In HIV Fusion Deal With Trimeris

Roche is looking to expand its presence in the HIV/AIDS arena through an agreement with Durham, N.C.-based Trimeris for the development of a new class of antivirals called HIV-fusion inhibitors.